The supplement manufacturing giant said the sales figure would range from $3.05 billion to $3.07 billion and consolidated EBITDA for the fiscal year ended September 30, 2012 is forecast to range between $556 million and $566 million. These figures compared with a final sales figure in 2011 of $2.96 billion.
The company expected capital expenditures for the year to range between $90 million and $95 million and cash and cash equivalents are estimated to be between $313 million and $317 million. Debt was expected to stand at $2.16 billion. These preliminary figures have not been audited, the company said. The final report is expected to be filed by Nov. 30.
NBTY declined to discuss the preliminary financial data when contacted by NutraIngredients-USA. But in May, when discussing NBTY's financial performance, Chief Financial Officer Michael Collins told NutraIngredients-USA that NBTY continued to "significantly outperform the market." Tuesday's preliminary figures appear to be in line with what the company reported in May.
In addition the preliminary financial data, the company announced an amendment to its credit agreement. The amendment will allow NBTY’s parent company to issue and sell contingent cash pay senior notes in a private placement, in an amount currently contemplated to be approximately $500 million.
The debt on NBTY’s balance sheet rose significantly in 2011 with the completion the acqusition by Carlyle. That was the most recent in a series of strategic acquisitions, according to the company’s 2011 annual report. NBTY, the leading global vertically integrated manufacturer, distributor and retailer of a broad line of vitamins, nutritional supplements and related products in the United States, has acquired more than 30 companies in or businesses engaged in the manufacturing, retail and direct response sale of nutritional supplements.